Seungil Paik

Seungil Paik

Auto-generated profile, based on publicly available information

Seungil Paik

Yonsei University College of Medicine

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2020 in Science
Verified
Journal Article
Closed access
LMLukas F. Mager
Lukas F. Mager
RBRegula Burkhard
Regula Burkhard
NPNicola Pett
Nicola Pett
NCNoah C. A. Cooke
Noah C. A. Cooke
KBKirsty Brown
Kirsty Brown
KMKathy D. McCoy
Kathy D. McCoy
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427

24 March 2014 in Stem Cells and Development
Verified
Journal Article
Closed access
SLSeulgi Lee
Seulgi Lee
DYDong Suk Yoon
Dong Suk Yoon
SPSeungil Paik
Seungil Paik
KLKyoung-Mi Lee
Kyoung-Mi Lee
YJYeonsue Jang
Yeonsue Jang
JLJin Woo Lee
Jin Woo Lee
The chondrogenic differentiation process of human mesenchymal stem cells (hMSCs) passes through multiple stages, which are carried out by various factors and their interactions. Recently, microRNAs that regulate chondrogenic differentiation have been reported. However, microRNA that regulates SRY-related high mobility group-box gene 9 (Sox9), a chondrogenic key factor, has not been identified in hMSC. In this study, we identified that microRNA-495 (miR-495) is an important regulator of hMSC chondrogenic differentiation. In our microarray, miR-495 was downregulated during transforming growth factor (TGF)-β3-induced chondrogenic differentiation of hMSCs in vitro. We found that there is an miR-495 binding site in the 3′ untranslated region (3′UTR) of Sox9 . We confirmed opposite expression between miR-495 and Sox9 by using real-time polymerase chain reaction. Further, overexpression of miR-495 inhibited Sox9 expression, and repression of miR-495 increased expression of Sox9 in SW1353 cells and hMSCs. Additionally, luciferase analysis revealed that miR-495 directly binds to the Sox9 3′UTR, and we confirmed a seed sequence of miR-495 on the Sox9 3′UTR. Subsequently, overexpression of miR-495 repressed the expression of the extracellular matrix (ECM) protein, such as type II collagen (Col2A1), aggrecan, and proteoglycan products, whereas inhibition of miR-495 increased their expression. Collectively, this study indicates that miR-495 directly targets Sox9, ultimately leading to the regulation of chondrogenic differentiation in hMSCs.

22 January 2010 in Stem Cells and Development
Verified
Journal Article
Closed access
DYDong Suk Yoon
Dong Suk Yoon
JYJe Hyun Yoo
Je Hyun Yoo
YKYun Hee Kim
Yun Hee Kim
SPSeungil Paik
Seungil Paik
CHChang Dong Han
Chang Dong Han
JLJin Woo Lee
Jin Woo Lee
Cyclooxygenase-2 (COX-2) inhibitors suppress bone repair and bone formation by suppressing angiogenesis as well as potentially interfering with osteoblast and osteoclast functions. In spite of these reports, there is a controversy over the exact effects of COX-2 inhibitors on bone formation processes itself. This work was designed to investigate the effect of COX-2 inhibitor on osteogenesis of human bone marrow-derived mesenchymal stem cells (MSC). MSCs in osteogenesis were treated with COX-2 inhibitor (celecoxib and naproxen) in the absence or presence of interleukin-1β (IL-1β), which was used to induce inflammation. Following differentiation, alkaline phosphatase (ALP) and calcium contents of IL-1β-treated MSC were significantly reduced by high doses of COX-2 inhibitors compared with the low-dose group. However, in non-inflammatory-conditioned MSCs, ALP and calcium contents were not reduced by COX-2 inhibitors. The mRNA expression of Runx2/Cbf α 1, Dlx5 , and osteocalcin was also decreased by COX-2 inhibitors in inflammatory-conditioned MSCs and showed a significant decrease for the high dose while they remained constant in the non-inflammatory-conditioned MSCs. These data indicate that the osteogenic potential of MSC is inhibited/delayed by the treatment of high-dose NSAIDs under inflammatory conditions.

6 July 2012 in Stem Cells and Development
Verified
Journal Article
Closed access
SPSeungil Paik
Seungil Paik
HJHo Sun Jung
Ho Sun Jung
SLSeulgi Lee
Seulgi Lee
DYDong Suk Yoon
Dong Suk Yoon
MPMin Sung Park
Min Sung Park
JLJin Woo Lee
Jin Woo Lee
MicroRNAs are small molecules, about 17–23 nucleotides in length, that act as translational regulators of their target gene. By binding to a target, microRNAs are known to either inhibit translation or induce degradation of the target. Despite the great interest in microRNAs, however, the exact targets of each individual microRNA in different processes remain largely unknown. In this study, we determined that the lymphoid enhancer-binding factor-1 ( LEF-1 ) was expressed during the chondrogenesis of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) and sought to identify a novel microRNA targeting this gene. Through subsequent studies, we have identified, for the first time, one particular microRNA, miR-449a, that recognizes and regulates the expression of LEF-1 in a dose-dependent and sequence-specific manner. In addition, we observed that the inhibition of LEF-1 via miR-449a led to the subsequent repression of Sox 9 , which is a well-established regulator of chondrogenesis. Collectively, this study demonstrated that miR-449a directly targets LEF-1, which in turn affects the expression of Sox 9 , ultimately leading to the proper regulation of the differentiation and chondrogenesis of human MSCs (hBM-MSCs).

16 March 2019 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
SPSeungil Paik
Seungil Paik
RSRishi Somvanshi
Rishi Somvanshi
UKUjendra Kumar
Ujendra Kumar

4 May 2011 in Stem Cells and Development
Verified
Journal Article
Closed access
HJHo Sun Jung
Ho Sun Jung
YLYoo Jeong Lee
Yoo Jeong Lee
YKYun Hee Kim
Yun Hee Kim
SPSeungil Paik
Seungil Paik
Jae-woo KimJae-woo Kim
Jae-woo Kim
JLJin Woo Lee
Jin Woo Lee
Adipogenesis is largely dependent on the signal transducers and activators of transcription (STAT) pathway. However, the molecular mechanism of the STAT pathway in the adipogenesis of human bone marrow-derived stromal cells (hBMSCs) remains not well understood. The purpose of this research was to characterize the transcriptional regulation involved in expression of STAT5A and STAT5B during adipogenesis in hBMSCs and 3T3-L1 cells. The expression of STAT5A and STAT5B increases with the onset of adipogenesis in hBMSCs and 3T3-L1 cells. The PPAR response elements regulatory element of STAT5A exists at a promoter region ranging from −346 to −101, and the CCAAT/enhancer-binding protein (C/EBP) regulatory element is located at −196 to −118 of the STAT5B promoter. C/EBPβ and C/EBPα bound to the STAT5B promoter region, whereas peroxisome proliferator-activated receptor γ (PPARγ) bound to STAT5A. RNA interference of STAT5A completely blocked differentiation, whereas the inhibition of STAT5B only partially blocked differentiation. We propose that C/EBPα, C/EBPβ, and PPARγ control adipogenesis by regulating STAT5B and STAT5A and that STAT5A is necessary, whereas STAT5B plays a supplementary role during adipogenesis. Further, the regulation of PPARγ-STAT5 by C/EBPβ signaling seems to be the crucial adipogenesis pathway-initiating cascade of the various adipogenic genes.